Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Boehringer Ingelheim
Colorcon
Dow
McKesson

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Patent: RE43316

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE43316
Title:Diabetes management system and method for controlling blood glucose
Abstract: A diabetes management system for predicting a future blood glucose value of a patient and for recommending a corrective action to the patient when the future blood glucose value lies outside of a target range. The system includes a patient-operated apparatus for measuring blood glucose values and for storing data relating to insulin doses administered to the patient. The apparatus predicts the patient\'s future blood glucose value based upon the patient\'s current blood glucose value, the fraction of insulin action remaining from the insulin doses, and the patient\'s insulin sensitivity. The apparatus also determines the corrective action for the patient when the predicted blood glucose value lies outside of a target range. The system also includes a physician computer in communication with the apparatus for receiving the blood glucose values and insulin dose data and for calculating an adjusted insulin sensitivity for use in subsequent predictions.
Inventor(s): Brown; Stephen J. (Woodside, CA), Worthington; David L. (La Honda, CA)
Assignee: Health Hero Network, Inc. (Palo Alto, CA)
Application Number:10/950,226
Patent Claims:see list of patent claims

Details for Patent RE43316

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 003 2018-10-19   Start Trial Health Hero Network, Inc. (Palo Alto, CA) 2017-01-10 RX search
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 002 2018-10-19   Start Trial Health Hero Network, Inc. (Palo Alto, CA) 2017-01-10 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 001 2018-10-19   Start Trial Health Hero Network, Inc. (Palo Alto, CA) 2017-01-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Harvard Business School
Medtronic
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.